Atorvastatin for the treatment of plaque-type psoriasis.

scientific article published in November 2011

Atorvastatin for the treatment of plaque-type psoriasis. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1592/PHCO.31.11.1045
P698PubMed publication ID22026392

P2093author name stringMohsen Rezaei Hemami
Mania Radfar
Toktam Faghihi
Amir Hoshang Ehsani
Zohre Mehrabian
P2860cites workPsoriasis: targeting therapy towards the inflammatory cascadeQ37768402
Psoriasis and cardiovascular diseasesQ37776250
Psoriasis: from pathogenesis to novel therapeutic approachesQ37789387
Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance.Q37792117
Statins in dermatology.Q37801956
Simvastatin in psoriasis: ambiguous effectsQ43007088
Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: Comparison of adverse event–free response days in the CHAMPION trialQ45129897
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?Q53517010
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasisQ28270369
Intensive versus moderate lipid lowering with statins after acute coronary syndromesQ29619716
Clinical improvement in psoriasis with treatment of associated hyperlipidemiaQ34158912
Anti-inflammatory and immunomodulatory effects of statins.Q34163404
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialQ34550538
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).Q34585521
Psoriasis assessment tools in clinical trialsQ35579443
Statins: novel additions to the dermatologic arsenal?Q35798211
Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiencesQ35843827
Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and reviewQ36879686
Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approachQ37242931
Immunomodulation by statins: mechanisms and potential impact on autoimmune diseasesQ37541814
Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies.Q37742713
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditionsQ37743164
Do structural differences in statins correlate with clinical efficacy?Q37768005
P433issue11
P407language of work or nameEnglishQ1860
P304page(s)1045-1050
P577publication date2011-11-01
P1433published inPharmacotherapyQ7180800
P1476titleAtorvastatin for the treatment of plaque-type psoriasis.
P478volume31

Reverse relations

cites work (P2860)
Q41038631Adherence to statins and the risk of psoriasis: a population-based cohort study
Q50333986Atorvastatin as an adjuvant with betamethasone valerate reduces disease severity and cardiovascular risks in Psoriasis
Q64080894Comparison of efficacy and safety of atorvastatin 5% lotion and betamethasone 0.1% lotion in the treatment of scalp seborrheic dermatitis
Q38749538Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis
Q64946734Linking CD1-Restricted T Cells With Autoimmunity and Dyslipidemia: Lipid Levels Matter.
Q28535430Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach
Q38113531Rational for statin use in psoriatic patients.
Q42555894Statin use and osteoarthritis
Q38056160The association between psoriasis and dyslipidaemia: a systematic review
Q89687364The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials

Search more.